Search by Drug Name, NDC or Jcode
Internal Navigation
HCPCS Details
HCPC | J0491 |
Short Description | Inj anifrolumab-fnia 1mg |
Long Description | Injection, anifrolumab-fnia, 1 mg |
Pricing indicator | 51 |
Coverage code | C |
ASC payment group code | YY |
BETOS2 code | O1E |
Action code | N |
Type of service | 1 |
Effective date | 2022-04-01 |
Date Added | 2022-04-01 |
HCPCS/NDC Cross-Walk
NDC | HCPC | Description | Drug Name | Labeler Name | HCPCS Dosage | PKG Size | PKG QTY | Bill Units | Bill Units PKG |
---|---|---|---|---|---|---|---|---|---|
00310304000 | J0491 | Inj anifrolumab-fnia 1mg | Saphnelo | ASTRAZENECA | 1 mg | 2 | 1 | 300 | 300 |
HCPCS Billing Calculator
Dosage given to patient (per dose) | |
---|---|
HCPCS Dosage | 1 mg |
HCPCS/CPT Billing Units | 1 |
Total doses ordered | |
Billing Units | 1 |
Drug Details
-
Anifrolumab is used with other medications to treat moderate to severe systemic lupus erythematosus (SLE or lupus; an autoimmune disease in which the immune system attacks healthy parts of the body such as joints, skin, blood vessels, and organs) in adults. Anifrolumab injection is in a class of medications called monoclonal antibodies. It works by blocking the activity of a certain protein in people with SLE.